Avacta Group Plc (OTCMKTS:AVCTF) Short Interest Update

Avacta Group Plc (OTCMKTS:AVCTF) was the recipient of a large decline in short interest in June. As of June 30th, there was short interest totaling 31,567 shares, a decline of 62.2% from the June 15th total of 83,496 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Avacta Group Stock Performance

Shares of AVCTF opened at $1.00 on Wednesday. Avacta Group has a twelve month low of $0.45 and a twelve month high of $1.23. The company has a 50 day moving average of $1.03 and a two-hundred day moving average of $0.91.

Avacta Group Company Profile

Avacta Group plc is a UK-based biotechnology company specializing in the discovery, development and commercialization of Affimer® biotherapeutics and diagnostic reagents. The company’s proprietary Affimer platform uses small, engineered protein scaffolds that can be tailored to bind specifically to target molecules, offering an alternative to traditional antibodies. Avacta operates two core divisions: Avacta Therapeutics, which focuses on novel treatments in oncology and immune-related diseases, and Avacta Analytical, which develops reagents and point-of-care diagnostic tests.

In its diagnostics business, Avacta has applied the Affimer technology to lateral flow assays, most notably for rapid detection of viral pathogens such as SARS-CoV-2.